Lawrence J Coppey
Overview
Explore the profile of Lawrence J Coppey including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
40
Citations
1313
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Obrosov A, Coppey L, Shevalye H, Yorek M
J Diabet Complicat Ther
. 2023 Jun;
1(1).
PMID: 37332358
Objective: Feeding mice a diet containing high fat and high sucrose has been promoted as a good model for type 2 diabetes. This study sought to determine the effect of...
2.
Nuno D, Coppey L, Yorek M, Lamping K
Physiol Rep
. 2018 Aug;
6(15):e13820.
PMID: 30105819
We tested whether dietary fatty acids alter membrane composition shifting localization of signaling pathways within caveolae to determine their role in vascular function. Wild type (WT) and caveolin-1-deficient mice (cav-1...
3.
Davidson E, Coppey L, Shevalye H, Obrosov A, Yorek M
J Diabetes Res
. 2018 Jul;
2018:2967127.
PMID: 30057911
In this study, we wanted to extend our investigation of the efficacy of fish oil with or without salsalate on vascular and neural complications using a type 2 diabetic rat...
4.
Davidson E, Coppey L, Shevalye H, Obrosov A, Yorek M
Diabetes
. 2018 Jun;
67(8):1616-1626.
PMID: 29941448
Previously, we had shown that a vasopeptidase inhibitor drug containing ACE and neprilysin inhibitors was an effective treatment for diabetic vascular and neural complications. However, side effects prevented further development....
5.
Obrosov A, Coppey L, Shevalye H, Yorek M
J Neurol Neurophysiol
. 2018 Feb;
8(6).
PMID: 29423332
Objective: Fish oil is enriched in omega-3 polyunsaturated fatty acids primarily eicosapentaenoic and docosahexaenoic fatty acids. Metabolites of these two polyunsaturated fatty acids include the E and D series resolvins....
6.
Coppey L, Shevalye H, Obrosov A, Davidson E, Yorek M
J Diabetes Investig
. 2018 Feb;
9(5):1033-1040.
PMID: 29412513
Aims/introduction: Peripheral neuropathy is a common complication of diabetes and also occurs in 30% of human obese individuals with impaired glucose tolerance. Even though peripheral neuropathy affects both sexes, most...
7.
Davidson E, Coppey L, Shevalye H, Obrosov A, Kardon R, Yorek M
Cornea
. 2017 May;
36(6):725-731.
PMID: 28476051
Purpose: This study investigated the efficacy of monotherapy versus combination of menhaden oil, α-lipoic acid, and enalapril on corneal sensation and morphometry and other neuropathy-related endpoints in a rat model...
8.
Qi W, Keenan H, Li Q, Ishikado A, Kannt A, Sadowski T, et al.
Nat Med
. 2017 Apr;
23(6):753-762.
PMID: 28436957
Diabetic nephropathy (DN) is a major cause of end-stage renal disease, and therapeutic options for preventing its progression are limited. To identify novel therapeutic strategies, we studied protective factors for...
9.
Obrosov A, Shevalye H, Coppey L, Yorek M
Free Radic Res
. 2017 Apr;
51(4):360-367.
PMID: 28376643
In this study, we sought to determine the efficacy of tempol on multiple neuropathic endpoints in a diet-induced obese mouse, a model of pre-diabetes, and a high-fat fed low-dose streptozotocin...
10.
Yorek M, Obrosov A, Shevalye H, Coppey L, Kardon R, Yorek M
Neuropharmacology
. 2016 Dec;
116:122-131.
PMID: 28025096
We have previously demonstrated that enalapril, α-lipoic acid and menhaden (fish) oil has potential as a treatment for diabetic peripheral neuropathy. In this study we sought to determine the efficacy...